Commentary: Championing integrity in pharmaceutical publishing
This article was originally published in Scrip
ISMPP's annual meeting brings its more than 700 members together, including representatives from pharmaceutical companies, medical communication agencies and medical/bioscience publishing. Thus it creates a unique gathering of business professionals involved in publishing peer-reviewed articles.
You may also be interested in...
The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.